Nitracrine

Nitracrine

SCHEMBL22587584

CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12.N.N

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.98
CHRM2 P08172 1/20 0.98
CHRM1 P11229 1/20 0.98
DRD2 P14416 1/20 0.98
ADRA2B P18089 1/20 0.98
ADRA2C P18825 1/20 0.98
CHRM3 P20309 1/20 0.98
MAOA P21397 1/20 0.98
HTR2A P28223 1/20 0.98
HTR2C P28335 1/20 0.98
ADORA2A P29274 1/20 0.98
ADRA1A P35348 1/20 0.98
DRD3 P35462 1/20 0.98
HTR2B P41595 1/20 0.98
PDE4D Q08499 1/20 0.98
KCNH2 Q12809 1/20 0.98
RAD52 P43351 3/20 0.64
KMT2A Q03164 3/20 0.64
RAB9A P51151 2/20 0.64
NPC1 O15118 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitracrine SCHEMBL29399539 0.99 HRH1 (1.00) HRH1CHRM2CHRM1DRD2ADRA2B
Nitracrine SCHEMBL8807 0.99 HRH1 (1.00) HRH1CHRM2CHRM1DRD2ADRA2B
Nitracrine SCHEMBL2500143 0.98 HRH1 (0.98) HRH1CHRM2CHRM1DRD2ADRA2B
Nitracrine SCHEMBL1652148 0.98 HRH1 (0.98) HRH1CHRM2CHRM1DRD2ADRA2B
Nitracrine SCHEMBL29711499 0.98 HRH1 (0.98) HRH1CHRM2CHRM1DRD2ADRA2B
Nitracrine SCHEMBL1230044 0.97 HRH1 (0.96) HRH1CHRM2CHRM1DRD2ADRA2B
Hydrochloric Acid SCHEMBL3341307 0.94 HRH1 (0.90) HRH1CHRM2CHRM1DRD2ADRA2B
Hydrochloric Acid SCHEMBL31237957 0.90 HRH1 (0.83) HRH1CHRM2CHRM1DRD2ADRA2B
SCHEMBL7877715 0.89 CHRM2 (0.80) HRH1CHRM2CHRM1DRD2ADRA2B
SCHEMBL7877922 0.89 CHRM2 (0.80) HRH1CHRM2CHRM1DRD2ADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021110085-A1 METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION 深圳艾欣达伟医药科技有限公司 2021-06-10 WO claimed
WO-2021110085-A1 METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION 深圳艾欣达伟医药科技有限公司 2021-06-10 WO disclosed
WO-2020216319-A1 USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR 中国医药大学 2020-10-29 WO disclosed